World's Best Scientists 2026 revealed!
Adelheid Cerwenka

Adelheid Cerwenka

D-Index & Metrics

Immunology

D-Index
65
Citations
16708
World Ranking
2828
National Ranking
187

Overview

Adelheid Cerwenka is affiliated with Heidelberg University in Germany and has a significant research presence in the fields of immunology and microbiology, with substantial contributions to medicine. Their research output includes 68 publications focusing on immunology and microbiology and 32 on medicine.

The scientist's work spans several subfields such as immunology, oncology, molecular biology, hepatology, and epidemiology. Their main research themes center on immune cell function and interaction, immune cells in cancer, T-cell and B-cell immunology, CAR-T cell therapy research, IL-33, ST2, and ILC pathways, immunotherapy and immune responses, and immune response and inflammation.

Recent publications by Cerwenka include:

  • "Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity," 2020, Immunity
  • "Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8," 2022, Science Advances
  • "Type 1 Treg cells promote the generation of CD8+ tissue-resident memory T cells," 2020, Nature Immunology
  • "Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression," 2022, Circulation
  • "TGF-β2 silencing to target biliary-derived liver diseases," 2020, Gut

Cerwenka's frequent coauthors include Ana Stojanovic, Carolina De La Torre, Michael Platten, Tomáš Hofman, and Carsten Sticht. Their collaborative relationships have contributed to a diverse range of publications.

The scientist's work has been published frequently in venues such as bioRxiv (Cold Spring Harbor Laboratory), Journal for ImmunoTherapy of Cancer, OncoImmunology, Frontiers in Immunology, and the European Journal of Immunology.

Best Publications

  • Natural killer cells, viruses and cancer.

    Adelheid Cerwenka;Lewis L. Lanier

  • Retinoic Acid Early Inducible Genes Define a Ligand Family for the Activating NKG2D Receptor in Mice

    Adelheid Cerwenka;Alexander B.H Bakker;Terri McClanahan;Janet Wagner

  • Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

    Adelheid Cerwenka;Jody L. Baron;Lewis L. Lanier

  • Natural killer cell memory in infection, inflammation and cancer

    Adelheid Cerwenka;Lewis L. Lanier

  • NKG2D ligands in tumor immunity

    N Nausch;A Cerwenka

  • Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth

    Eva Schlecker;Ana Stojanovic;Christian Eisen;Christian Quack

  • Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

    Jing Ni;Matthias Miller;Ana Stojanovic;Natalio Garbi;Natalio Garbi

  • Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands

    Marco Wendel;Ioanna E. Galani;Elisabeth Suri-Payer;Adelheid Cerwenka

  • Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke.

    Arthur Liesz;Wei Zhou;Éva Mracskó;Simone Karcher

  • DAP12-Deficient Mice Fail to Develop Autoimmunity Due to Impaired Antigen Priming

    Alexander B.H. Bakker;Robert M. Hoek;Adelheid Cerwenka;Bianca Blom

  • Ligands for natural killer cell receptors: redundancy or specificity.

    Adelheid Cerwenka;Lewis L. Lanier

  • Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.

    Jing Ni;Jing Ni;Xi Wang;Ana Stojanovic;Ana Stojanovic;Qin Zhang

  • Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2

    Sonja Textor;Nathalie Fiegler;Annette Arnold;Angel Porgador

  • Migration Kinetics and Final Destination of Type 1 and Type 2 CD8 Effector Cells Predict Protection against Pulmonary Virus Infection

    Adelheid Cerwenka;Tammy M. Morgan;Allen G. Harmsen;Richard W. Dutton

  • Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease

    Francesca Vinchi;Francesca Vinchi;Francesca Vinchi;Milene Costa da Silva;Giada Ingoglia;Sara Petrillo

  • Radiation effects on antitumor immune responses: current perspectives and challenges.

    Thomas Walle;Rafael Martinez Monge;Adelheid Cerwenka;Daniel Ajona

  • The TREM-1/DAP12 pathway.

    Anja S. Tessarz;Adelheid Cerwenka

  • Tricking the balance: NK cells in anti-cancer immunity

    Jens Pahl;Adelheid Cerwenka

  • In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines

    Adelheid Cerwenka;Laura L. Carter;Joyce B. Reome;Susan L. Swain

  • Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44

    Benyamin Rosental;Michael Brusilovsky;Uzi Hadad;Dafna Oz

  • Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: Homing properties rather than initial frequencies are crucial

    Adelheid Cerwenka;Tammy M. Morgan;Richard W. Dutton

Frequent Co-Authors

Carsten Watzl
Carsten Watzl TU Dortmund University
Lewis L. Lanier
Lewis L. Lanier University of California, San Francisco
Angel Porgador
Angel Porgador Ben-Gurion University of the Negev
Martina U. Muckenthaler
Martina U. Muckenthaler Heidelberg University
Richard W. Dutton
Richard W. Dutton University of Massachusetts Chan Medical School
Gerhard Moldenhauer
Gerhard Moldenhauer German Cancer Research Center
Peter Schirmacher
Peter Schirmacher University Hospital Heidelberg
Alexander Steinle
Alexander Steinle Goethe University Frankfurt
Frank Momburg
Frank Momburg German Cancer Research Center
Antje Sucker
Antje Sucker University of Duisburg-Essen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to diverse healthcare careers, many of which can benefit from nursing qualifications. For those looking to pivot into nursing, several affordable and flexible online options exist. For instance, online adn programs for non nurses are designed specifically to help individuals with non-nursing backgrounds transition smoothly into the nursing profession.

Accelerated routes are also becoming increasingly popular among career changers. Programs such as the easiest accelerated nursing programs help expedite the process, enabling students to complete their Bachelor of Science in Nursing quickly and begin practicing sooner.

For those seeking quicker entry-level credentials, there are plenty of options. The easiest lpn programs to get into offer foundational nursing training and certification, often with flexible scheduling to accommodate working students.

Advancing further into specialized roles, the easiest np programs to get into provide pathways to become nurse practitioners, combining clinical practice with an advanced scope of care. These pathways complement immunology study by integrating clinical expertise with immunological knowledge.

Best Scientists Citing Adelheid Cerwenka

Trending Scientists